News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Strategic focus on COCO-model with a nationwide reach of 501 stores
CSPC will receive an upfront payment of $100 million from AstraZeneca
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
This is used to treat central diabetes insipidus and bedwetting
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Subscribe To Our Newsletter & Stay Updated
